Pharmacological treatment of Pulmonary Arterial Hypertension

Folyóirat címe
Folyóirat ISSN
Kötet címe (évfolyam száma)

Pulmonary hypertension (PH) is characterized by a mean pulmonary arterial pressure (PAP) of 20 mm Hg or higher, as determined via right heart catheterization, measured at rest. Categorized within group 1 pulmonary hypertension (PH), PAH is a debilitating condition marked by the pathological restructuring of the pulmonary arteries, ultimately resulting in right ventricular failure. Regardless of the underlying illness, PAH is almost consistently linked to worsening symptoms and a higher death rate. PH lacks a distinctive clinical sign that is pathognomonic. The most common symptom, which almost all patients experience even in the face of modest hemodynamic anomalies, is persistent dyspnea on exertion. Other common symptoms are fatigue, weakness, angina, palpitations, and syncope. Occasionally, hoarseness of the voice may be observed, attributed to the compression of the left laryngeal nerve by the dilated pulmonary artery. In the most severe cases, signs of right heart failure may manifest, including venous jugular distension, hepatomegaly, lower limb edema, ascites, and generalized edema.